TAFA5/FAM19A5 Antibody (463102) [Alexa Fluor™ Plus 647]

• Reactivity: Hu
• Clone: 463102
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor Plus 647

TAFA5/FAM19A5 Antibody (463102) [Alexa Fluor™ Plus 647] Summary

• Specificity: Detects TAFA5/FAM19A5 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human TAFA2, 3, or 4 is observed.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Rat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TAFA5/FAM19A5 Antibody (463102) [Alexa Fluor™ Plus 647]

• Chemokine-like protein TAFA-5
• FAM19A5
• family with sequence similarity 19 (chemokine (C-C motif)-like), member A5
• QLLK5208
• TAFA protein 5
• TAFA5
• TAFA-5
• UNQ5208

Background

TAFA5 (also FAM19A5) is a 14 kDa type I transmembrane protein and member of the FAM19/TAFA family of chemokine-like proteins (1). Human TAFA5 is 132 amino acids (aa) in length. It contains a 15 aa extracellular domain, a 23 aa transmembrane sequence, and a 95 aa cytoplasmic region. Alternate splicing produces two additional isoforms. Isoform 2, a secreted form, has a 31 aa substitution for residues 1‑38 in isoform 1. Isoform 3 has an eight aa substitution for residues 1‑87 in isoform1. Human TAFA5 is 100% aa identical to mouse TAFA5 (1). Within the TAFA family, TAFA5 is the most distinct member, while TAFAs 2, 3, and 4 are the most closely related members (1). Real-time PCR analysis indicates that TAFA5 mRNA expression is restricted to the central nervous system (CNS), with the highest level in the basal ganglia and cerebellum (1). The biological functions of TAFA family members are not yet known, but there are a few tentative hypotheses. First, TAFAs may modulate immune responses in the CNS by functioning as brain-specific chemokines, and may act with other chemokines to optimize the recruitment and activity of immune cells in the CNS (1). Second, TAFAs may represent a novel class of neurokines that act as regulators of immune nervous cells (1‑2). Finally, TAFAs may control axonal sprouting following brain injury (1).

1. Tang, Y.T. et al. (2004) Genomics 83:727.
2. Benveniste, E. (1998) Cytokine Growth Factor Rev. 9:259.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.